Thalidomide can reduce refractory gastrointestinal bleeding from gastrointestinal arteriovenous malformation.
Vol. 4 No. 2 (2020), Kritikoki Aztertutako Testuak
Vol. 4 No. 2 (2020)

Thalidomide can reduce refractory gastrointestinal bleeding from gastrointestinal arteriovenous malformation.

Kritikoki Aztertutako Testuak
Published 2020-12-30
Asier Mitxelena Bengoetxea
Osakidetza
Angela Vallejo Sagaseta de Ilúrdoz
PDF (Euskara)

Keywords

Gastrointestinal arteriovenous malformation
gastrointestinal bleeding
anemia
Thalidomide.

How to Cite

Mitxelena Bengoetxea, A., & Vallejo Sagaseta de Ilúrdoz, A. (2020). Thalidomide can reduce refractory gastrointestinal bleeding from gastrointestinal arteriovenous malformation. Osagaiz: Osasun-Zientzien Aldizkaria, 4(2). Retrieved from https://aldizkariak.ueu.eus/index.php/osagaiz/article/view/298
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Comparing to iron alone Thalidomide can reduce gastrointestinal bleeding (–67%), red blood cell transfusion (–37%), hospitalizations (–54%), and active gastrointestinal bleeding (–46%). Because the number of patients is small further research is needed.

PDF (Euskara)